Simplifying Global Compliance
FDA Offers Draft Guidance for Developing Abuse-Deterrent Opioids
Washington Drug Letter
Drug manufacturers developing opioids with abuse-deterrent properties should use three categories of premarket studies to provide enough data on a drug’s prospects for reducing abuse or misuse, according to new draft FDA guidance.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing